Valuation: Avacta Group Plc

Market Cap 291M 386M 348M 321M 550M 36.21B 563M 3.85B 1.54B 19.39B 1.45B 1.42B 61.71B P/E 2026 *
-8.65x
P/E 2027 * -14.4x
Enterprise Value 285M 378M 341M 315M 539M 35.47B 552M 3.77B 1.5B 19B 1.42B 1.39B 60.45B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.82%
Yield 2026 *
-
Yield 2027 * -
1 day+0.67%
1 week+8.09%
Current month-0.66%
1 month-6.09%
3 months-6.82%
6 months-29.71%
Current year+3.62%
1 week 52
Extreme 52
63
1 month 52
Extreme 52
70
Current year 48
Extreme 48
92
1 year 48
Extreme 48
92
3 years 26
Extreme 26
148
5 years 26
Extreme 26
187.98
10 years 13
Extreme 13
291.8
Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Operating Officer - -
Director TitleAgeSince
Chairman 58 22/06/2026
Director/Board Member 62 06/07/2026
Director/Board Member 61 14/09/2026
Date Insider Type Main position Quantity % Market Cap. Importance
02/09/24 Sell

Chief Financial Officer

500,000 0.1393%
02/09/24 Free

Chief Executive Officer

3,600,000 1.0027%
02/09/24 Exercice

Chief Financial Officer

500,000 0.1393%
Change 5-day change 1-year change 3-year change Capi.($)
+0.67%+8.09%-22.55%-57.68% 386M
-1.06%-0.07%+60.76%+68.61% 67.53B
+1.51%+8.95%+14.22%+93.13% 60.74B
+0.42%-1.01%+20.01%+98.33% 55.66B
-0.95%+11.17%+22.21%+110.93% 47.97B
-0.23%+4.07%+25.63%+40.08% 45.24B
-6.40%-9.51%+181.99%+816.79% 39.08B
+1.97%+3.50%+25.78%+50.98% 35.34B
-1.64%-3.36%+78.73%+55.58% 33.45B
+1.05%+9.77%-37.66%+408.42% 26.49B
Average +0.24%+1.91%+36.91%+168.52% 41B
Weighted average by Cap. +0.13%+1.64%+43.60%+168.20%

Financials

2026 *2027 *
Net sales - -
Net income -35.42M -47.05M -42.41M -39.18M -67.01M -4.41B -68.66M -470M -187M -2.36B -177M -173M -7.52B -14.1M -18.73M -16.88M -15.59M -26.67M -1.76B -27.33M -187M -74.48M -941M -70.28M -68.78M -2.99B
Net Debt -5.94M -7.88M -7.11M -6.57M -11.23M -740M -11.51M -78.69M -31.36M -396M -29.59M -28.96M -1.26B 5.65M 7.51M 6.77M 6.25M 10.7M 704M 10.96M 74.95M 29.87M 377M 28.19M 27.59M 1.2B
Projected Income Statement - Annual - Avacta Group Plc
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
81
Date Price Change Volume
12/11/26 GBX 60.10 +0.67% 1,444,832
11/11/26 GBX 59.70 +10.56% 5,136,558
10/11/26 GBX 54.00 +1.12% 3,107,308
09/11/26 GBX 53.40 -0.74% 2,157,191
06/11/26 GBX 53.80 -3.24% 5,762,518
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Avacta Group Plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.5970GBP
Average target price
0.9050GBP
Spread / Average Target
+51.59%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Avacta Group Plc
  1. Stock Market
  2. Stocks
  3. AVCT Stock